Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmogenic Inflammatory Cardiomyopathy: A Review

Ventricular arrhythmias (VA) are commonly associated with structural heart disease and have substantial impact on patient outcomes and health system costs. Within the realm of cardiomyopathy (CM), there has been substantial progress with respect to ischaemic CM (ICM) in the understanding of infarct related scar biology and scar-mediated ventricular tachycardia (VT).

Holter Monitoring and Loop Recorders: From Research to Clinical Practice

Since the 1960s, Holter monitoring has been a cornerstone for diagnosing suspected arrhythmias in patients of all ages.1 The most common monitoring systems allow the continuous registration of three or more leads for 24–48 hours; newer Holter monitors allow continuous electrocardiogram (ECG) registration for 2 weeks.1 Extending the time of ECG registration will increase the diagnostic yield of Holter monitoring, especially for those rhythm disturbances that are infrequent but recurrent.1,2 This need for a prolonged ECG monitoring has been a

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes

Arrhythmogenic cardiomyopathy (ACM) is usually referred to as arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).1A first historical description was made in 1736, whereas its first modern description dates back to 1982.2 Initially, ACM was thought to be an embryological malformation.3 Yet in recent years it became evident that the pathophysiology of an ongoing genetically determined myocardial atrophy did not fit the theory of a congenital myocardial aplasia.

Bridging the Knowledge Gaps in Arrhythmogenic Cardiovascular Conditions: The Critical Role of Registries

One of the fundamental principles of evidence-based medicine is that clinical care should be based on data derived from appropriately designed trials, registries, and observational data from patients. The best available evidence is then used to develop guidelines for clinical care, assess quality, measure performance, and improve patient outcomes. The highest level of evidence in clinical medicine, also known as Level of Evidence A, is derived from multiple prospective randomized clinical trials (RCTs) or from meta-analysis.

Decompensated Heart Failure in Pregnancy

‘Heart failure’ is a term that may be loosely or precisely defined. The development of pulmonary oedema does not necessarily indicate a cardiac cause and of the cardiac causes for pulmonary oedema, not all can be attributed to left ventricular failure.1 The majority of women developing symptoms and signs of heart failure during pregnancy have no known pre-existing cardiomyopathy. This article describes the cardiac causes of pulmonary oedema presenting in pregnancy with reference to other differential diagnoses.